文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

使效果可见——针对 OX40 的纳米抗体可用于成像活化的 T 细胞。

Making the effect visible - OX40 targeting nanobodies for imaging of activated T cells.

机构信息

Pharmaceutical Biotechnology, University Tübingen, Tübingen, Germany.

Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.

出版信息

Front Immunol. 2024 Oct 15;15:1480091. doi: 10.3389/fimmu.2024.1480091. eCollection 2024.


DOI:10.3389/fimmu.2024.1480091
PMID:39474429
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11518761/
Abstract

PURPOSE: Human OX40 (hOX40/CD134), a member of the TNF receptor superfamily, is mainly expressed on activated T lymphocytes. Triggered by its ligand OX40L (CD252), it provides costimulatory signals that support the differentiation, proliferation and long-term survival of T cells. Besides being a relevant therapeutic target, hOX40 is also an important biomarker for monitoring the presence or infiltration of activated T cells within the tumor microenvironment (TME), the inflammatory microenvironment (IME) in immune-mediated diseases (IMIDs) and the lymphatic organs. Here, we developed novel single domain antibodies (nanobodies, Nbs) targeting hOX40 to monitor the activation status of T cells by molecular imaging. METHODS: Nbs against hOX40 (hOX40-Nbs) were selected from an immunized Nb-library by phage display. The identified hOX40-Nbs were characterized , including determination of their specificity, affinity, stability, epitope recognition and their impact on OX40 signaling and T cell function. A lead candidate was site-specifically conjugated with a fluorophore via sortagging and applied for noninvasive optical imaging (OI) of hOX40-expressing cells in a xenograft mouse model. RESULTS: Our selection campaign revealed four unique Nbs that exhibit strong binding affinities and high stabilities under physiological conditions. Epitope binning and domain mapping indicated the targeting of at least two different epitopes on hOX40. When analyzing their impact on OX40 signaling, an agonistic effect was excluded for all validated Nbs. Incubation of activated T cells with hOX40-Nbs did not affect cell viability or proliferation patterns, whereas differences in cytokine release were observed. OI with a fluorophore-conjugated lead candidate in experimental mice with hOX40-expressing xenografts demonstrated its specificity and functionality as an imaging probe. CONCLUSION: Considering the need for advanced probes for noninvasive monitoring of T cell activation dynamics, we propose, that our hOX40-Nbs have a great potential as imaging probes for noninvasive and longitudinal diagnostics. Quantification of OX40 T cells in TME or IME will provide crucial insights into the activation state of infiltrating T cells, offering a valuable biomarker for assessing immune responses, predicting treatment efficacy, and guiding personalized immunotherapy strategies in patients with cancer or IMIDs.

摘要

目的:人 OX40(hOX40/CD134)是肿瘤坏死因子受体超家族的成员,主要表达于活化的 T 淋巴细胞。其配体 OX40L(CD252)与之结合后提供共刺激信号,支持 T 细胞的分化、增殖和长期存活。hOX40 不仅是一个相关的治疗靶点,也是监测肿瘤微环境(TME)、免疫介导疾病(IMIDs)中的炎症微环境(IME)以及淋巴器官中活化 T 细胞存在或浸润的重要生物标志物。在这里,我们开发了针对 hOX40 的新型单域抗体(纳米抗体,Nbs),通过分子成像来监测 T 细胞的激活状态。

方法:通过噬菌体展示从免疫的 Nb 文库中筛选针对 hOX40 的 Nbs。对鉴定出的 hOX40-Nbs 进行了特性分析,包括特异性、亲和力、稳定性、表位识别以及对 OX40 信号和 T 细胞功能的影响。选择一个先导候选物通过 sortagging 特异性地与荧光团偶联,并应用于异种移植小鼠模型中表达 hOX40 的细胞的非侵入性光学成像(OI)。

结果:我们的筛选活动揭示了四个独特的 Nbs,它们在生理条件下具有很强的结合亲和力和高稳定性。表位分组和结构域映射表明,这些 Nbs 靶向 hOX40 上至少两个不同的表位。在分析它们对 OX40 信号的影响时,排除了所有验证的 Nbs 的激动作用。hOX40-Nbs 孵育活化的 T 细胞不会影响细胞活力或增殖模式,但观察到细胞因子释放的差异。在表达 hOX40 的异种移植实验小鼠中,用荧光团偶联的先导候选物进行 OI 证明了其作为成像探针的特异性和功能。

结论:考虑到对用于非侵入性监测 T 细胞激活动力学的先进探针的需求,我们提出,我们的 hOX40-Nbs 具有作为非侵入性和纵向诊断成像探针的巨大潜力。TME 或 IME 中 OX40 T 细胞的定量将提供对浸润 T 细胞激活状态的深入了解,为评估免疫反应、预测治疗效果以及指导癌症或 IMIDs 患者的个性化免疫治疗策略提供有价值的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/ee7dfb28c7de/fimmu-15-1480091-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/341e8dd6f8fc/fimmu-15-1480091-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/378445b53881/fimmu-15-1480091-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/7c7a8cb445ea/fimmu-15-1480091-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/a98426d6aadb/fimmu-15-1480091-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/000027f6c6e6/fimmu-15-1480091-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/ee7dfb28c7de/fimmu-15-1480091-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/341e8dd6f8fc/fimmu-15-1480091-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/378445b53881/fimmu-15-1480091-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/7c7a8cb445ea/fimmu-15-1480091-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/a98426d6aadb/fimmu-15-1480091-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/000027f6c6e6/fimmu-15-1480091-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4729/11518761/ee7dfb28c7de/fimmu-15-1480091-g006.jpg

相似文献

[1]
Making the effect visible - OX40 targeting nanobodies for imaging of activated T cells.

Front Immunol. 2024

[2]
Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.

Nucleic Acid Ther. 2012-10-31

[3]
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.

J Immunother Cancer. 2020-12

[4]
Single-Domain Antibodies for Targeting, Detection, and Imaging of Human CD4 Cells.

Front Immunol. 2021

[5]
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.

J Immunother Cancer. 2024-7-4

[6]
Noninvasive Imaging OX40 Activated T Cells Provides Early Warning of Rheumatoid Arthritis.

Mol Imaging Biol. 2023-8

[7]
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.

J Immunother Cancer. 2020-9

[8]
OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.

Mol Cancer. 2015-2-15

[9]
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Mol Cancer Ther. 2018-3-15

[10]
Enhancement of OX40-induced apoptosis by TNF coactivation in OX40-expressing T cell lines in vitro leading to decreased targets for HIV type 1 production.

AIDS Res Hum Retroviruses. 2008-3

引用本文的文献

[1]
Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines.

Mol Cancer. 2025-3-4

本文引用的文献

[1]
Specific imaging of CD8 + T-Cell dynamics with a nanobody radiotracer against human CD8β.

Eur J Nucl Med Mol Imaging. 2024-12

[2]
Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies.

Antibodies (Basel). 2024-2-1

[3]
Two birds with one stone: human SIRPα nanobodies for functional modulation and imaging of myeloid cells.

Front Immunol. 2023

[4]
Phase I Study of [Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I).

J Nucl Med. 2023-9

[5]
Advances in PET imaging of cancer.

Nat Rev Cancer. 2023-7

[6]
Noninvasive Imaging OX40 Activated T Cells Provides Early Warning of Rheumatoid Arthritis.

Mol Imaging Biol. 2023-8

[7]
T-cell activation-induced marker assays in health and disease.

Immunol Cell Biol. 2023-7

[8]
The emerging role of regulatory cell-based therapy in autoimmune disease.

Front Immunol. 2022

[9]
Imaging of Activated T Cells.

J Nucl Med. 2023-1

[10]
Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy.

Front Immunol. 2022

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索